drugset / Trial / NCT06949800
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
Phase 2
Not yet recruiting
90 enrolled
University of California, San Francisco
Exegi Pharma, LLC · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population
Timeline
- Start
- 2026-09-01
- Primary completion
- 2027-05-31
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VSL#3 | Other / unclassified | — | Oral |